UBS rated Buy Warner Chilcott (NASDAQ: WCRX) on 02/11/2013. Previously UBS rated Buy Warner Chilcott (NASDAQ: WCRX) on 11/10/2011., when the stock price was $16.82. Since then, Warner Chilcott has gained 14.21% as of 05/17/2013's recent price of $19.21.
If you would have followed the previous UBS's recommendation on WCRX, you would have gained 14.2% of your investment in 554 days.

Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women?s healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. In October 2009, the Company announced it completed the acquisition of The Procter & Gamble Company?s global branded prescription pharmaceutical business.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.

Marked as spam